GTx is a company of experienced individuals who are dedicated to developing novel targeted hormonal therapies to provide better medicines for patients. The Company focuses on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. It is developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy.
To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, GTx has a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.

Type
Public
HQ
Memphis, US
Founded
1997
Size (employees)
26 (est)
Website
gtxinc.com
GTx was founded in 1997 and is headquartered in Memphis, US
Report incorrect company information

Key People/Management at GTx

Marc S. Hanover

Marc S. Hanover

President and Chief Operating Officer

GTx Office Locations

GTx has an office in Memphis
Memphis, US (HQ)
175 Toyota Plaza
Show all (1)
Report incorrect company information

GTx Financials and Metrics

GTx Financials

USD

Net income (Q3, 2017)

(8.5 m)

EBIT (Q3, 2017)

(8.5 m)

Market capitalization (23-Apr-2018)

303.3 m

Cash (30-Sep-2017)

53.4 m
GTx's current market capitalization is $303.3 m.
Annual
USDFY, 2016

General and administrative expense

2.3 m

R&D expense

4.6 m

Operating expense total

6.9 m

EBIT

(6.9 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

2 m2 m2.1 m2 m2.3 m2.1 m2 m2.6 m

R&D expense

3 m3.8 m4 m4.1 m4.6 m4.2 m4.4 m5.9 m

Operating expense total

5 m5.9 m6.1 m6.1 m6.9 m6.3 m6.4 m8.5 m

EBIT

(5 m)(5.9 m)(6.1 m)(6.1 m)(6.9 m)(6.3 m)(6.4 m)(8.5 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.5 m17.9 m14.1 m8.9 m

Accounts Receivable

3.6 m

Inventories

442 k856 k2.6 m2.4 m

Current Assets

15.2 m50.2 m31.9 m24.3 m
Quarterly
USDQ1, 2016Q3, 2017

Cash

12.1 m53.4 m

Inventories

2 m

Current Assets

26.6 m55.7 m

PP&E

12 k57 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(42.1 m)(39.4 m)(18.7 m)(17.7 m)

Depreciation and Amortization

384 k102 k43 k28 k

Accounts Payable

(899 k)(296 k)(130 k)838 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(48 m)34.9 m2.1 m(6.1 m)(6.9 m)(6.3 m)

Depreciation and Amortization

4 k

Accounts Payable

1.3 m619 k992 k179 k438 k797 k184 k521 k1.4 m1.2 m514 k603 k

Cash From Operating Activities

(4.8 m)
USDY, 2017

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information